Osteitis Deformans
📧 Sign up to get email alerts when something new happens for Osteitis Deformans.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2018-12-12EMA Withdrawn: Zoledronic acid Teva Pharma (zoledronic acid) — Teva B.V.
EMA withdrew zoledronic acid Teva Pharma (zoledronic acid) from the market in 2018 for indications including osteoporosis, osteitis deforman…
-
EMA withdrawal · 2016-08-08EMA Withdrawn: Zoledronic acid Teva Generics (zoledronic acid monohydrate) — Teva Generics B.V
Withdrawn EMA entry for zoledronic acid Teva Generics (zoledronic acid monohydrate) with therapeutic use in osteoporosis and osteitis deform…
-
EMA withdrawal · 2008-11-20EMA Withdrawn: Forcaltonin (recombinant salmon calcitonin) — Unigene UK Ltd.
Forcaltonin (recombinant salmon calcitonin) has been withdrawn from the EMA; previously indicated for hypercalcemia, osteitis deformans, and…